Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Kingsley Lawrence D | director | M-Exempt | 2,203 @ $114.17 | $251.5K |
Daily · Wilder smoothing
| Sep 4, 26 |
| Kingsley Lawrence D |
| director |
| S-Sale |
| 2,203 @ $532.08 |
| $1.17M |
| Sep 4, 26 | Kingsley Lawrence D | director | M-Exempt | 2,203 @ $114.17 | $251.5K |
| Aug 20, 26 | Emerson Andrew | officer: EVP, CFO and Treasurer | M-Exempt | 265 @ $178.26 | $47.24K |
| Aug 20, 26 | Emerson Andrew | officer: EVP, CFO and Treasurer | F-InKind | 86 | — |
| Aug 20, 26 | Emerson Andrew | officer: EVP, CFO and Treasurer | M-Exempt | 265 @ $178.26 | $47.24K |
| Jul 30, 26 | Hooley Joseph L | director | A-Award | 49 @ $558.80 | $27.38K |
| Jun 1, 26 | Fennell George | officer: Executive Vice President | M-Exempt | 639 | — |
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 63.16 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 90.91 | Oscillator | Sell |
| Williams %R (14) | -16.43 | Oscillator | Sell |
| MACD (12, 26, 9) | 4.33 (Hist 5.55) | Oscillator | Strong Buy |
| Average Directional Index (14) | 18.15 (+DI 32.5 / -DI 12.2) | Trend | Neutral |
| EMA 20 | 530.15 | MA | Strong Buy |
| SMA 20 | 525.69 | MA | Strong Buy |
| EMA 50 | 534.16 | MA | Strong Buy |
| SMA 50 | 534.63 | MA | Strong Buy |
| SMA 200 | 579.07 | MA | Strong Sell |
Stock news · updated daily
IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
Diversify Advisory Services LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,346 shares of the company's stock after acquiring an additional 1,234 shares during the
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Assenagon Asset Management S.A. raised its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.9% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 256,362 shares of the company's stock after buying an additional 73,129 shares during the quarter. Assenagon Asset Management S.A. owned about 0.33%
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.
Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 3.94 | 4.27 | Beat 8.4% | $1.22B |
| May 5, 2026 | 3.41 | 3.47 | Beat 1.8% | $1.14B |
| Feb 2, 2026 | 2.93 | 3.08 | Beat 5.1% | $1.09B |
| Nov 3, 2025 | 3.14 | 3.40 | Beat 8.3% | $1.11B |
| Aug 4, 2025 | 3.28 | 3.63 | Beat 10.7% | $1.11B |
| May 1, 2025 | 2.85 | 2.96 | Beat 3.9% | $998.4M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 9, 2026 | 2026-09-09 17:00:08 | View |
| 4 | Aug 24, 2026 | 2026-08-24 17:00:10 | View |
| 10-Q | Aug 4, 2026 | 2026-08-04 16:16:29 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 06:32:59 | View |
| 4 | Aug 3, 2026 | 2026-08-03 17:00:08 | View |
| 4 | Jun 2, 2026 | 2026-06-02 17:00:13 | View |
| SD | Jun 1, 2026 | 2026-06-01 16:00:04 | View |
| 8-K | May 15, 2026 | 2026-05-15 16:00:10 | View |
| 4 | May 14, 2026 | 2026-05-14 17:01:01 | View |
| 4 | May 14, 2026 | 2026-05-14 17:00:55 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | IDXX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 39.0x | 54.0x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 37.6x | EPS est. 14.77 | In line |
| Price / Book | 27.6x | 44.7x | Discount |
| Price / Sales | 9.6x | 12.3x | Discount |
| EV / EBITDA | 27.6x | 38.4x | Discount |
| Return on equity | 72.0% | — | Top tier |
| Gross margin | 62.4% | 60.2% | In line |
| Debt / Equity | 0.68 | 1.18 | Moderate |
| Piotroski / Altman Z | 9/9 | Z 20.13 | Safe zone |
Discounted cash flow model
Current price $555.80
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 16, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 11, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 5, 26 | UBS | maintain | Neutral | Neutral |
| Aug 5, 26 | Citigroup | maintain | Neutral | Neutral |
| Jul 27, 26 | UBS | maintain | Neutral | Neutral |
| Apr 28, 26 | UBS | maintain | Neutral | Neutral |
| Mar 31, 26 | Stifel | maintain | Buy | Buy |
| Feb 9, 26 | Piper Sandler | maintain | Neutral | Neutral |
| Feb 5, 26 | Barclays | maintain | Overweight | Overweight |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure